Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer

References

• Alberg, A. J., Brock, M. V., Ford, J. G., Samet, J. M., & Spivack, S. D. (2013). Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e1S–e29S. https://doi.org/10.1378/chest.12-2345
   PubMed Web of Science ®Google Scholar
• Allouche, A. (2011). Software news and updates gabedit — a graphical user interface for computational chemistry softwares. Journal of Computational Chemistry, 32(1), 174–182. https://doi.org/10.1002/jcc.21600
   PubMed Web of Science ®Google Scholar
• Almahli, H., Hadchity, E., Jaballah, M. Y., Daher, R., Ghabbour, H. A., Kabil, M. M., Al-Shakliah, N. S., & Eldehna, W. M. (2018). Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Bioorganic Chemistry, 77, 443–456. https://doi.org/10.1016/j.bioorg.2018.01.034
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., Dinola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. Journal of Chemical Physics, 81(8), 3684–3690. https://doi.org/10.1063/1.448118
   Web of Science ®Google Scholar
• Bös, F., & Pleiss, J. (2009). Multiple molecular dynamics simulations of TEM β-lactamase: Dynamics and water binding of the Ω-loop. Biophysical Journal, 97, 2550–2558.
   PubMed Web of Science ®Google Scholar
• Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688. https://doi.org/10.1002/jcc.20290
   PubMed Web of Science ®Google Scholar
• Case, D. A., Walker, R. C., Cheatham, T. E., Simmerling, C., Roitberg, A., Merz, K. M., Luo, R., & Darden, T. (2018). ‘Amber 18’. University of California San Francisco.
   Google Scholar
• Choi, E. B., Yang, A. Y., Kim, S. C., Lee, J., Choi, J. K., Choi, C., & Kim, M. Y. (2016). PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair. Oncogene, 35(35), 4569–4579. https://doi.org/10.1038/onc.2016.3
   PubMed Web of Science ®Google Scholar
• Cockcroft, X. L., Dillon, K. J., Dixon, L., Drzewiecki, J., Kerrigan, F., Loh, V. M., Martin, N. M. B., Menear, K. A., & Smith, G. C. M. (2006). Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorganic & Medicinal Chemistry Letters, 16(4), 1040–1044. https://doi.org/10.1016/j.bmcl.2005.10.081
   PubMed Web of Science ®Google Scholar
• Comen, E. A., & Robson, M. V. (2010). Poly (ADP-Ribose) polymerase inhibitors in Triple-Negative Breast Cancer. The Cancer Journal,16, 48–52.
   Google Scholar
• Damale, M. G., Patil, R., Ansari, S. A., Alkahtani, H. M., & Almehizia, A. A. (2019). Identification of dual site inhibitors of tankyrase through virtual screening of protein-ligand interaction fingerprint (PLIF) – derived pharmacophore models. Molecular Dynamics, and ADMET Studies', 1, 1–11.
   Google Scholar
• David, C. C., & Jacobs, D. J. (2014). Principal component analysis: a method for determining the essential dynamics of proteins. Methods in Molecular Biology, 1084, 193–226.
   PubMedGoogle Scholar
• Dziadkowiec, K. N., Gąsiorowska, E., Nowak-Markwitz, E., & Jankowska, A. (2016). PARP inhibitors: Review of mechanisms of action and BRCA1/2 mutation targeting. Przeglad Menopauzalny = Menopause Review, 15(4), 215–219. https://doi.org/10.5114/pm.2016.65667
   PubMedGoogle Scholar
• Exman, P., Barroso-Sousa, R., & Tolaney, S. M. (2019). Evidence to date: Talazoparib in the treatment of breast cancer. OncoTargets and Therapy, 12, 5177–5187. https://doi.org/10.2147/OTT.S184971
   PubMed Web of Science ®Google Scholar
• Ferraris, D. V. (2010). Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. from concept to clinic. Journal of Medicinal Chemistry, 53(12), 4561–4584. https://doi.org/10.1021/jm100012m
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Halder, A. K., Saha, A., Das Saha, K., & Jha, T. (2015). Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 33(8), 1756–1779. https://doi.org/10.1080/07391102.2014.969772
   PubMed Web of Science ®Google Scholar
• Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4(1), 17. https://doi.org/10.1186/1758-2946-4-17
   PubMed Web of Science ®Google Scholar
• Hottiger, M. O., Hassa, P. O., Lüscher, B., Schüler, H., & Koch-Nolte, F. (2010). Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends in Biochemical Sciences, 35(4), 208–219. https://doi.org/10.1016/j.tibs.2009.12.003
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the Performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations . Journal of Chemical Information and Modeling, 51(1), 69–82. https://doi.org/10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Jagtap, P., & Szabo, C. (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Reviews. Drug Discovery, 4(5), 421–440. https://doi.org/10.1038/nrd1718
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Kirubakaran, P., Arunkumar, P., Premkumar, K., & Muthusamy, K. (2014). Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach. Molecular bioSystems, 10(10), 2699–2712. https://doi.org/10.1039/c4mb00309h
   PubMedGoogle Scholar
• Kollman, P. A., I., Massova, C., Reyes, B., Kuhn, S., Huo, L., Chong, M., Lee, T., Lee, Y., Duan, W., Wang, O., Donini, P., Cieplak, J., Srinivasan, D. A., Case, & T. E. Cheatham, (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33(12), 889–897. https://doi.org/10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Langelier, M. F., Ruhl, D. D., Planck, J. L., Kraus, W. L., & Pascal, J. M. (2010). The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. The Journal of Biological Chemistry, 285(24), 18877–18887. https://doi.org/10.1074/jbc.M110.105668
   PubMed Web of Science ®Google Scholar
• Langelier, M. F., Servent, K. M., Rogers, E. E., & Pascal, J. M. (2008). A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. The Journal of Biological Chemistry, 283(7), 4105–4114. https://doi.org/10.1074/jbc.M708558200
   PubMed Web of Science ®Google Scholar
• Loh, V. M., Cockcroft, X. L., Dillon, K. J., Dixon, L., Drzewiecki, J., Eversley, P. J., Gomez, S., Hoare, J., Kerrigan, F., Matthews, I. T. W., Menear, K. A., Martin, N. M. B., Newton, R. F., Paul, J., Smith, G. C. M., Vile, J., & Whittle, A. J. (2005). Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorganic & Medicinal Chemistry Letters, 15(9), 2235–2238. https://doi.org/10.1016/j.bmcl.2005.03.026
   PubMed Web of Science ®Google Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Malyuchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015). PARP1 Inhibitors: Anti-tumor drug design(1) Malyuchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., and Studitskiy, V. M. (2015) PARP1 Inhibitors: Anti-tumor drug design. Acta Naturae 7, 27–37. Acta Naturae, 7(3), 27–37. https://doi.org/10.32607/20758251-2015-7-3-27-37
   PubMed Web of Science ®Google Scholar
• Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X-l., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., Javaid, H., Kerrigan, F., Knights, C., Lau, A., Loh, V. M., Matthews, I. T. W., Moore, S., O’Connor, M. J., Smith, G. C. M., & Martin, N. M. B. (2008). 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1'. Journal of Medicinal Chemistry, 51(20), 6581–6591. https://doi.org/10.1021/jm8001263
   PubMed Web of Science ®Google Scholar
• Nilov, D., Maluchenko, N., Kurgina, T., Pushkarev, S., Lys, A., Kutuzov, M., Gerasimova, N., Feofanov, A., Švedas, V., Lavrik, O., & Studitsky, V. M. (2020). Molecular mechanisms of PARP-1 inhibitor 7-methylguanine. International Journal of Molecular Sciences, 21, 1–11.
   Google Scholar
• Nilov, D., Pushkarev, S. V., Gushchina, V., Manasaryan, G. A., & Kirsanov, K. I., Švedas, V. K. (2020). Modeling of the enzyme – substrate complexes of human poly (ADP Ribose) Polymerase 1. Biochemistry 85, 99–107.
   PubMed Web of Science ®Google Scholar
• Ohmoto, A., & Yachida, S. (2017). Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets and Therapy, 10, 5195–5208. https://doi.org/10.2147/OTT.S139336
   PubMed Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Postel-Vinay, S., Bajrami, I., Friboulet, L., Elliott, R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J. C., Lord, C. J., & Ashworth, A. (2013). A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, 32(47), 5377–5387. https://doi.org/10.1038/onc.2013.311
   PubMed Web of Science ®Google Scholar
• Ratnam, K., & Low, J. (2007). Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 13(5), 1383–1389. https://doi.org/10.1158/1078-0432.CCR-06-2260
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095. https://doi.org/10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010). PARP inhibition: PARP1 and beyond. Nature Reviews. Cancer, 10(4), 293–301. https://doi.org/10.1038/nrc2812
   PubMed Web of Science ®Google Scholar
• Salmas, R. E., Unlu, A., Yurtsever, M., Noskov, S. Y., & Durdagi, S. (2016). In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(1), 112–120. https://doi.org/10.3109/14756366.2015.1005011
   PubMed Web of Science ®Google Scholar
• Sandhu, S. K., Yap, T. A., & de Bono, J. S. (2010). Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. European Journal of Cancer (Oxford, England: 1990), 46(1), 9–20. https://doi.org/10.1016/j.ejca.2009.10.021
   PubMed Web of Science ®Google Scholar
• Sarkar, S., Tribedi, P., & Bhadra, K. (2021). Structure-activity insights of harmine targeting DNA, ROS inducing cytotoxicity with PARP mediated apoptosis against cervical cancer, anti-biofilm formation and in vivo therapeutic study. Journal of Biomolecular Structure and Dynamics, 1–23. https://doi.org/10.1080/07391102.2021.1874533
   Google Scholar
• Seifert, E. (2014). OriginPro 9.1: Scientific data analysis and graphing software-software review. Journal of Chemical Information and Modeling, 54(5), 1552. https://doi.org/10.1021/ci500161d
   PubMed Web of Science ®Google Scholar
• Sittel, F., Jain, A., & Stock, G. (2014). Principal component analysis of molecular dynamics: On the use of Cartesian vs. internal coordinates. Journal of Chemical Physics, 141. DOI https://doi.org/10.1063/1.4885338
   Google Scholar
• Walsh, C. (2018). 'Targeted therapy for ovarian cancer: The rapidly evolving landscape of PARP inhibitor use. Minerva Ginecologica, 70(2), 150–170. https://doi.org/10.23736/S0026-4784.17.04152-1
   PubMed Web of Science ®Google Scholar
• Wang, S., Wang, H., Davis, B. C., Liang, J., Cui, R., Chen, S. J., & Xu, Z. X. (2011). PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochemical and Biophysical Research Communications, 412(2), 379–384. https://doi.org/10.1016/j.bbrc.2011.07.107
   PubMed Web of Science ®Google Scholar
• Webb, B., & Sali, A. (2016). Comparative protein structure modeling using MODELLER. Current Protocols in Bioinformaycis, 2016, 5.6.1–5.6.37.
   Google Scholar